Astal Laboratories has signed a Letter of Intent (LoI) with Switzerland-based Immuna Therapeutics GmbH for the exclusive India rights to next-generation CAR-T cell therapies, including TriCAR-T platforms. The proposed collaboration covers technology transfer, localization of manufacturing, clinical development, and commercialization in India. The initiative supports company’s long-term strategy to expand into high-value advanced therapies and cell and gene therapy platforms.
Astal estimates the collaboration will generate incremental revenue of approximately Rs 300 crore upon implementation, driven by rising demand for advanced oncology treatments and improved access through localized manufacturing. The partnership positions the company at the forefront of next-generation immuno-oncology in India while creating a scalable platform for future cell therapy programs.
Astal Laboratories (Formerly Known as Macro International) is a dynamic newcomer to the pharmaceutical industry’s bulk drug segment.
